Faster, cheaper and finer DNA sequencing — and a big investment from some well-known venture capital and angel investment names — is positioning an early-stage molecular diagnostics company in San Francisco’s Mission Bay to offer a test providing a much earlier peek at immune system problems.
No comments:
Post a Comment